Short blood-thinner course after stenting for narrowed vertebral arteries
Studies a 3-month blood-thinner course after stenting for vertebral artery narrowing in adults.
Plain-language title generated from the registry record
Registry title: Drug Eluting Stenting and Short Dual Antiplatelet Therapy for Preventing Recurrent Stroke in Vertebral Stenosis Registry Study
Key facts
- Where
- Beijing, ChinaSee the site
Where in China
- Beijing Tiantan HospitalBeijing, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Beijing Tiantan Hospital
- Trial code
- NCT06683300
- Record updated
- 12 November 2024
- Original description
This is a prospective, multi-center, registry study exploring the duration of dual antiplatelet therapy (DAPT) after drug-eluting stent(DES) treatment of symptomatic vertebral artery atherosclerotic stenosis. The trial will be conducted in approximately 30 interventional neurology centers in China.Read full original descriptionShow less
Drug Eluting Stenting and Short Dual Antiplatelet Therapy for Preventing Recurrent Stroke in Vertebral Stenosis Registry Study
This is a prospective, multi-center, registry study exploring the duration of dual antiplatelet therapy (DAPT) after drug-eluting stent(DES) treatment of symptomatic vertebral artery atherosclerotic stenosis. The trial will be conducted in approximately 30 interventional neurology centers in China.
Currently, there is no consensus regarding the duration of DAPT after drug-eluting stent treatment for vertebral artery stenosis(VAS). The objective of this study is to standardize clinical medication by shortening the duration of DAPT, thereby reducing the bleeding risk and medication burden for patients, while ensuring that there is no increase in ischemic events.
Inclusion: Age ≥18 years old, gender unlimited; Based on clinical and imaging evidence, the investigators identified patients with symptomatic vertebral atherosclerotic stenosis who met the indications for the placement of drug-eluting vertebral artery stents; Patients or their guardians sign informed consent.
Exclusion: Patients with aneurysms that cannot be treated in advance or at the same time or are not suitable for surgery; Interventional or surgical procedures are planned within 90 days; Severe coagulation dysfunction, serious uncontrolled infection, serious systemic disease, uncontrolled hypertension, etc., are not suitable for surgery; Myocardial infarction or large-scale cerebral infarction occurred within 2 weeks; Combined with atrial fibrillation, or accompanied by serious heart, liver, kidney and lung diseases; Known contraindications to heparin, rapamycin, anesthesia and contrast agents; Life expectancy is less than 12 months; The researcher considers it inappropriate to participate in this study.